# DYSREGULATED NFKB PATHWAY SIGNALING IN MYELOPROLIFERATIVE NEOPLASMS

> **NIH NIH R01** · WASHINGTON UNIVERSITY · 2020 · $413,675

## Abstract

7. Project Summary/Abstract
Myeloproliferative neoplasms (MPNs) are chronic blood disorders that that can cause severe symptoms and
early death. New treatments have become available recently that help ameliorate symptoms, but they do not
reliably slow or halt disease progression. We seek to better understand what drives disease development and
progression in MPNs, so that we can develop better therapies for patients with these diseases.
Our preliminary data indicates that a signaling pathway called the NFkB pathway is abnormally activated in
MPNs. We hypothesize that this pathway contributes to the development and progression of MPNs. Therefore,
we have proposed a combination of mouse and human studies to determine how the NFkB pathway
contributes to MPN pathogenesis, and to evaluate whether inhibition of NFkB signaling may have potential
therapeutic benefits for MPN patients.

## Key facts

- **NIH application ID:** 9843520
- **Project number:** 5R01HL134952-03
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** Stephen Oh
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $413,675
- **Award type:** 5
- **Project period:** 2017-12-11 → 2022-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9843520

## Citation

> US National Institutes of Health, RePORTER application 9843520, DYSREGULATED NFKB PATHWAY SIGNALING IN MYELOPROLIFERATIVE NEOPLASMS (5R01HL134952-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9843520. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*